-
Nov 23, 2024 | 
onclive.com | Jordan Hansford
CommentaryVideoNovember 23, 2024Author(s):Jordan R. Hansford, MD, discusses health-related quality-of-life outcomes with tovorafenib in pediatric patients with BRAF-altered low-grade glioma. Our total scores are improved in multiple domains, including anxiety, cognition, and other features. Not only are we seeing great efficacy, which was presented previously, but diving into the QOL on this study is also showing the patients are feeling improved QOL with this new agent, as well."Jordan R.
-
Nov 17, 2024 | 
mja.com.au | Jordan Hansford |Santosh Valvi |Jasper Boer |Dong Anh Khuong
Med J Aust 2024; 221 (10): 520-523. || doi: 10.5694/mja2.52506 Published online: 18 November 2024 Each year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer.
-
Aug 7, 2024 | 
brnw.ch | Jordan Hansford |Nicholas G Gottardo |Paul Fisher
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
-
Jun 6, 2024 | 
nature.com | Dong-Anh Khuong-Quang |Chelsea Mayoh |Marie Wong |Sumanth Nagabushan |Veronica Yeung |Natacha Omer | +15 more
AbstractRecent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT).
-
Jun 6, 2024 | nature.com | Dong-Anh Khuong-Quang |Chelsea Mayoh |Marie Wong |Sumanth Nagabushan |Veronica Yeung |Natacha Omer | +15 more
AbstractRecent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT).
-
Mar 11, 2024 | 
nature.com | Lindsay B. Kilburn |Dong-Anh Khuong-Quang |Jordan Hansford |Pablo Hernáiz Driever |Simon T. Bailey |David Ziegler | +10 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02668-y, published online 17 November 2023. In the version of the article initially published, in the third paragraph of the “RAPNO criteria (secondary endpoints)” section, the text now reading “Thirteen (17.1%) patients initially had a best overall response of PD…” originally read “Thirty-one patients initially had PD…”. This has been corrected in the HTML and PDF versions of the article.
-
Nov 17, 2023 | 
nature.com | Lindsay B. Kilburn |Dong-Anh Khuong-Quang |Jordan Hansford |Pablo Hernáiz Driever |Simon T. Bailey |David Ziegler | +10 more
AbstractBRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated the efficacy of the oral, selective, central nervous system–penetrant, type II RAF inhibitor tovorafenib (420 mg m−2 once weekly; 600 mg maximum) in patients with BRAF-altered, relapsed/refractory pLGG.
-
Oct 24, 2023 | 
nature.com | Dominik Sturm |David Capper |Felipe Andreiuolo |Christian Kölsche |Philipp Sievers |Annika K Wefers | +17 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02255-1. Published online 16 March 2023. In the version of this article initially published, Arend Koch (Department of Neuropathology, Charité - Universitätsmedizin Berlin, Berlin, Germany), Martin U. Schuhmann (Department of Neurosurgery, University of Tuebingen, Tuebingen, Germany) and Ulrich W.
-
Sep 20, 2023 | 
nejm.org | Eric Bouffet |Jordan Hansford |Maria Luisa Garrè |Ashley Plant-Fox
September 21, 2023N Engl J Med 2023; 389:1108-1120 DOI: 10.1056/NEJMoa2303815 AbstractDetection of the BRAF V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (both as monotherapy and in combination with trametinib) has shown efficacy in recurrent pediatric low-grade glioma with BRAF V600 mutations, findings that warrant further evaluation of this combination as first-line therapy.
-
Aug 23, 2023 | 
onclive.com | Jordan Hansford
Jordan Hansford, MD, clinical lead, Neuro-Oncology Group, Royal Children’s Hospital Melbourne, discusses the phase 2 FIREFLY-1 trial (NCT04775485), which is investigating the pan-RAF inhibitor tovorafenib (DAY101) in children and young adults patients with low-grade glioma. At both the 2023 ASCO Annual Meeting and the 2023 SNO Pediatric Neuro-Oncology Research Conference, FIREFLY-1 investigators presented efficacy and safety findings from this 3-arm phase 2 trial, Hansford says.
